It's like trying to read tea leaves, but I just watched the Fox interview again, and NP says at one point that after seeing the M2M CD10 P2 results, the FDA and UK MHRA requested the interim analysis of the S2C CD12 P3 interim analysis results. What does this mean? Did the FDA and MHRA request to see the actual data and results of the S2C CD12 interim results? That would mean unblinding to the FDA/MHRA. I then watched Montefiore doctor Harish Seethamraju's video presentation. If the FDA actually requested the interim data, maybe Dr. Seethamraju's statement that the FDA is reviewing the unblinded data to the FDA as we speak is correct if the FDA requested it at the time of seeing the M2M CD10 results. I guess we will learn the answer to this and our other questions on Tuesday. Also, does anyone else find it peculiar that the last ProActive Investors interview was August 26, almost two months ago?